Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644
This examiner grants 78% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | Non-Final OA | Genentech, Inc. |
| 17275117 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING | Final Rejection | Georgia Tech Research Corporation |
| 19092659 | Treatment for colorectal cancer using immune checkpoint inhibitors | Non-Final OA | Mirror Biologics, Inc. |
| 17999898 | IMMUNOMODULATORY COMPLEX AND USES THEREOF FOR THERAPY | Non-Final OA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18251823 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | Non-Final OA | Washington University |
| 17639654 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients | Final Rejection | Cedars-Sinai Medical Center |
| 18248651 | BINDING MOLECULES THAT MULTIMERISE CD45 | Non-Final OA | UCB BIOPHARMA SRL |
| 18174925 | BISPECIFIC ANTIBODY FOR ICOS AND PD-L1 | Final Rejection | KYMAB LIMITED |
| 17727309 | ANTI-ICOS ANTIBODIES | Non-Final OA | Kymab Limited |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | Non-Final OA | Kymab Limited |
| 18452395 | BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS | Non-Final OA | Xencor, Inc. |
| 17819234 | NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY | Non-Final OA | CANCER RESEARCH TECHNOLOGY LIMITED |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | Final Rejection | Cancer Research Technology Limited |
| 18309700 | ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS | Non-Final OA | BEIGENE SWITZERLAND GMBH |
| 18365110 | TARGETING OF PERI-NECROTIC TUMOR CELLS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18278388 | PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF | Non-Final OA | JIANGXI JEMINCARE GROUP CO., LTD. |
| 18212218 | PD1-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF | Final Rejection | KAHR Medical Ltd. |
| 18265055 | NOVEL FORMULATIONS FOR ANTIBODIES | Non-Final OA | Hexal AG |
| 18190425 | Immunologic Treatment of Cancer | Non-Final OA | ImmunSYS, Inc. |
| 18121557 | INTESTINAL EXPRESSION OF PROGRAMMED DEATH LIGAND 1 | Non-Final OA | ENGENE, INC. |
| 18004613 | FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF | Non-Final OA | KANAPH THERAPEUTICS INC. |
| 18018778 | ANTI-CD133 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING TUMOR | Non-Final OA | Beijing Neurosurgical Institute |
| 18063521 | FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE | Non-Final OA | F-star Therapeutics Limited |
| 18061791 | ANTI-CD277 ANTIBODIES AND USES THEREOF | Non-Final OA | Nantes Université |
| 17779908 | METHODS AND PRODUCTS FOR REDUCING SIDE EFFECTS ASSOCIATED WITH USE OF IMMUNE AGONIST ANTIBODIES | Non-Final OA | The Flinders University of South Australia |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy